“Evolving Critical Documents – Part 3”
Session – 5
(90 minutes)
Organized by:
Pharma Institute of GMPs
12/6/2019 1
Points Covered
What is a Change Control?
Developing SOP for Change Control
Regulatory & GMP linkages
Examples
Exercise!!
12/6/2019 2
Management of Change Control
Do not misunderstand !
The Requirements have always been there,
It is just that "Change Control"
is now a
CENTER STAGE
(Source: PIGMP)
12/6/2019 3
Management of Change Control
Q1 Change Control System : What it is?
------------------------------------------------------------------
Managing to control a change in a
process/procedure/system through proper and
scientific justification, review, approval,
implementation, follow-up and closure
Q2 What is the objective of Change Control
System ?
To provide mechanism for on-going process
optimization / system improvement and ensure a
continuing state of process control
12/6/2019
(Source: PIGMP) 4
Management of Change Control
Q3 What types of changes can be covered?
------------------------------------------------------------------
Proposed changes to :
Processing Steps
Specifications & Test Procedures
Facilities and equipment
Support Systems (Includes computer hardware and
software)
Key / starting materials (includes vendor)
Packaging materials / configuration
12/6/2019 (Source: PIGMP) 5
Purpose of Change Control
Q4 What is the purpose of the Change Control
Program?
------------------------------------------------------------------
To prevent unauthorized modifications to a validated
system,
To evaluate proposed changes against development and
technology transfer documents,
To identify and evaluate all proposed changes to assess
their potential effects on the manufacturing process,
and
To determine if, and to what extent, revalidation is
needed
12/6/2019 (Source: PIGMP) 6
Purpose of Change Control
Q4 continued…..
------------------------------------------------------------------
To ensure that all documents affected by changes
are promptly revised and,
To determine the impact of changes on the
critical chemical, physical and microbiological
attributes of the product, such as :
- assay, impurity profile, stability, and physical
characteristics
(Source: PIGMP)
12/6/2019 7
Purpose of Change Control
Q5 What could be the probable effect of
changes to improve process yields?
------------------------------------------------------------------
Such proposed changes should be evaluated
carefully to determine if they result in new or
higher levels of impurities/degradation products
- The impurity / degradation profile of resulting
batches should be comparable
(Source: PIGMP)
12/6/2019 8
Purpose of Change Control
Q6 Could process changes affect analytical
methods?
------------------------------------------------------------------
Yes ! Process changes should also be evaluated to
ensure that these do not have an adverse affect on
analytical methods
The effect is due to increased interference caused by
new or higher levels of impurities / degradation
products and by-products
Analytical methods should be modified as necessary to
ensure that they are capable of detecting and
quantifying impurities / degradation products
12/6/2019 (Source: PIGMP) 9
Purpose of Change Control
Q7 What follow-up is required after changes to
manufacturing process are implemented?
------------------------------------------------------------------
In case, the manufacturing process changes affect
the critical attributes of the API,
1. Notify dosage form manufacturers,
2. Notify Regulatory bodies, if mfg process is
filed,
3. Revalidation (where required),
4. Prompt revision of other documents affected,
(Source: PIGMP)
12/6/2019 10
Purpose of Change Control
Q7 continued……
------------------------------------------------------------------
5. Careful evaluation of the first few batches
produced/tested under the change,
6. Generate data on stability profile, impurity
profile, crystal form, particle size, residual
solvents, etc.
(Source: PIGMP)
12/6/2019 11
Purpose of Change Control
Q8 Do we have guidelines to classify or categorize
Changes?
------------------------------------------------------------------
There are no clear guidelines !
a) The change control program should provide for a
classification scheme to evaluate changes in :
- Raw Materials, Intermediates, Packing Materials
- Manufacturing Sites
- Scale of Manufacturing
- Manufacturing Equipment
- Production processes
- Specifications-STPs
- Editorial changes (Source: PIGMP)
12/6/2019 12
Purpose of Change Control
Q8 continued…….
------------------------------------------------------------------
b) The classification procedure should be used to
determine what level of:
- testing,
- validation, and
- documentation
is needed to justify changes to a validated process
(Source: PIGMP)
12/6/2019 13
Purpose of Change Control
Q9 How do we, therefore, categorize
changes?
------------------------------------------------------------------
We can categorize into Minor, Moderate or Major,
depending on the nature and extent of the changes,
and the effects that these Changes could impart on
the process/product
Scientific judgment should determine what
additional testing and validation studies are needed
to justify a change in a validated process
12/6/2019 (Source: PIGMP) 14
Purpose of Change Control
Q10 What is a Minor Change?
------------------------------------------------------------------
MINOR CHANGE is that change which :
* Is unlikely to have a detectable impact on the critical
attributes of the API / Drug Product
* Does not shift the process in any discernible manner
* Can be implemented with minimal testing and
revalidation
* Can be reviewed and approved by QA at the facility level
* Is reported in Annual Reports and does not require FDA
approval
(Source: PIGMP)
12/6/2019 15
Purpose of Change Control
Q10 continued…..
------------------------------------------------------------------
Few examples of MINOR CHANGES :
a. Like-for-Like equipment replacements,
b. Non-critical process parameters,
c. Revision of specifications (non-critical attributes) as per
Process capability,
d. Revised Quantity of reagents/excipients,
marginally,
e. Editorial changes
(Source: PIGMP)
12/6/2019 16
Purpose of Change Control
Q11 What is a MAJOR CHANGE?
-----------------------------------------------------------------
MAJOR CHANGE is that change which :
* Is likely to have a detectable impact on the critical
attributes of the API/drug product, significantly
• Could shift the process in a discernible manner
(quality, yield, stability, impurity/degradation
profile, crystal form, particle size)
(Source: PIGMP)
12/6/2019 17
Purpose of Change Control
Q11 continued…… MAJOR CHANGE
------------------------------------------------------------------
* Warrants definite additional/major testing
and suitable revalidation studies to justify
changes,
* Reviewed by QA at the facility level and
approved by Corporate Groups, and
* Requires prior FDA approval
(Source: PIGMP)
12/6/2019 18
Purpose of Change Control
Q11 continued…… MAJOR CHANGE
------------------------------------------------------------------
* Few examples of MAJOR CHANGES:
Change in type of solvent used for final
crystallization (affects impurity profile, physical
attributes and other CQAs of API),
Replacement of equipment with different kind (not
like-to-like)
(Source: PIGMP)
12/6/2019 19
Purpose of Change Control
Q11 continued….. MAJOR CHANGE
------------------------------------------------------------
Change in Critical Process Parameter(s),
Revision of Critical Quality Parameter
(specification), such as Assay limit, Related
Substances limit
(Source: PIGMP)
12/6/2019 20
Purpose of Change Control
More Examples of Major Changes:
--------------------------------------------------------------
Revision of STP for Assay (potentiometric to
HPLC), for Related Substances (TLC to HPLC),
for Residual Solvents (GC to Head Space)
- Change in facility (site of manufacturing),
- Change in route of synthesis for API,
- Change of key RM/excipient source,
- Change in sequence of operations
(Source: PIGMP)
12/6/2019 21
Purpose of Change Control
Q12 What is a MODERATE CHANGE?
------------------------------------------------------------------
MODERATE CHANGE is that change which:
Is usually for Improvements to process, materials,
product or procedure;
Therefore, no reason to wait!
Does not require prior approval by the Regulatory
/ FDA before implementation,
The Agency will want to review it!
Can go in Annual Reports to FDA
(Source: PIGMP)
12/6/2019 22
Purpose of Change Control
MODERATE CHANGES:
------------------------------------------------------------------
Can be evaluated by QA at the facility*
These are called
"CHANGES BEING EFFECTED“
(Source: PIGMP)
12/6/2019 23
Purpose of Change Control
MODERATE CHANGES:
------------------------------------------------------------------
Few examples of Moderate Changes include:
- Improvements in yield,
- Improvements in CQAs,
- Improvements in Process capability/efficiency,
- Cost-effectiveness
(Source: PIGMP)
12/6/2019 24
Status of Change Control
Q13 Explain STATUS of Change
Control Management!
------------------------------------------------------------------
a) MATERIALS: (Change of Vendor, MOC,
Configuration, Dimension)
* Do not happen - Mostly Unreported?
b) EQUIPMENT:
* Most obvious changes are reported
* However, maintenance changes – Mostly
unreported !!
(Source: PIGMP)
12/6/2019 25
Status of Change Control
Q13 continued…
----------------------------------------------------
c) PROCEDURES:
* Usually well documented and controlled
* However, not well communicated
(Source: PIGMP)
12/6/2019 26
Status of Change Control
Q13 continued…
------------------------------------------------------------
d) ANALYTICAL TEST METHODS:
* Usually well documented and controlled,
* Because changes come from pharmacopoeia or
corporate/higher authority,
* Prompt thorough notification,
* Affects a small group only
(Source: PIGMP)
12/6/2019 27
Management of Change Control
Make No Mistake!
Change Control Is No Easy Task!
It Is Fraught With Peril!
It Must However Be Done!
----------------------------------------------
You Are Your Change Agent
(Source: PIGMP)
12/6/2019 28
THANKS!
For inquiries please contact –
Sumant Baukhandi, PhD
Director - Pharma Institute of GMPs
Director - pharmaACCESS
7, Phase-1, Vasant Vihar,
Dehradun-246 006
Uttarakhand State (India)
Landphone: 91-135 276 3092
Cellphone: 91- 99970 10901
Email ID:
[email protected];
[email protected]Website: www.pigmp.com
12/6/2019 29
